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Abstract
Background: The extensive use of neuromuscular blocking agents (NMBAs) during surgical procedures still leads to
potential residual paralyzing effects in the postoperative period. Indeed, neuromuscular monitoring in an intra-operative
setting is strongly advocated. Acetylcholinesterase inhibitors can reverse muscle block, but their short half-life may lead
to residual curarization in the ward, especially when intermediate or long-acting NMBAs have been administered.
Sugammadex is the first selective reversal drug for steroidal NMBAs; it has been shown to give full and rapid recovery of
muscle strength, thus minimizing the occurrence of residual curarization. Acceleromyography of the adductor pollicis is
the gold standard for detecting residual curarization, but it cannot be carried out on conscious patients. Ultrasonography
of diaphragm thickness may reveal residual effects of NMBAs in conscious patients.
Methods/design: This prospective, double-blind, single-center randomized controlled study will enroll patients (of
American Society of Anesthesiologists physical status I–II, aged 18–80 years) who will be scheduled to undergo deep
neuromuscular block with rocuronium for ear, nose, or throat surgery. The study’s primary objective will be to compare
the effects of neostigmine and sugammadex on postoperative residual curarization using two different tools: diaphragm
ultrasonography and acceleromyography of the adductor pollicis. Patients will be extubated when the train-of-four ratio is
> 0.9. Diaphragm ultrasonography will be used to evaluate the thickening fraction, which is the difference between the
end expiratory thickness and the end inspiratory thickness, normalized to the end expiratory thickness. Ultrasonography
will be performed before the initiation of general anesthesia, before extubation, and 10 and 30 min after discharging
patients from the operating room. The secondary objective will be to compare the incidence of postoperative
complications due to residual neuromuscular block between patients who receive neostigmine and those who receive
sugammadex.
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Discussion: Postoperative residual curarization is a topic of paramount importance, because its occurrence can cause
complications and increase the length of stay in hospital and the related costs. Diaphragm ultrasound assessment may
become a bedside integrative tool in the neuromuscular monitoring field to detect concealed residual curarization in
surgical patients who have received paralyzing agents.
Trial registration: EudraCT, 2013-004787-62. Registered on 18 June 2014, as “Evaluation of muscle function recovery after
deep neuromuscular blockade by acceleromyography of the adductor pollicis or diaphragmatic echography: comparison
between sugammadex and neostigmine.”
ClinicalTrials.gov, NCT02698969. Registered on 15 February 2016, as “Recovery of Muscle Function After Deep Neuromuscular
Block by Means of Diaphragm Ultrasonography and Adductor Pollicis Acceleromyography: Comparison of Neostigmine vs.
Sugammadex as Reversal Drugs.”
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Background
Non-depolarizing neuromuscular blocking agents
(NMBAs) are extensively used by anesthesiologists to
maintain deep neuromuscular block (dNMB) during
surgical operations. To avoid the postoperative residual
effects of NMBAs, muscle relaxants should be fully ca-
tabolized to inactive metabolites prior to extubation.
Nevertheless, when a patient is waking from general
anesthesia, it is possible that some of the administered
paralyzing agent is not completely transformed to its
inactive form at the level of neuromuscular junctions,
causing residual effects that can be difficult to
clinically diagnose without adequate neuromuscular
monitoring [1].
The use of intra-operative neuromuscular monitoring
when NMBAs are administered has been encouraged in
order to decrease postoperative residual curarization
(PORC) [2]. Acceleromyography, the most commonly
used method of quantitative monitoring, appraises
muscle acceleration responding to nerve stimulation by
train-of-four (TOF) and post-tetanic count (PTC)
methods [3]. For many years, a TOF ratio not greater
than 0.9 between the amplitude of the last stimulation
and that of the first one was used to define PORC. Des-
pite the fact that these types of monitoring are strongly
recommended, they are not regularly performed in the
operating room scenario [4, 5]. Furthermore, the TOF
test is unpleasant for patients when they are conscious.
The incidence of PORC ranges from 9 to 56.5% when
no reversal drug is administered [6]. For many years, re-
versing the NMBA effect has been carried out using an
acetylcholinesterase inhibitor (AChEI) such as neostig-
mine. These inhibitors, which increase acetylcholine
levels in the neuromuscular junction, antagonize the
paralyzing agent but do not hasten its metabolism.
Therefore, as a result of the unpredictable metabolism of
blocking drugs, a residual curarization may occur when
the AChEI effect has elapsed [7]. Indeed, an observa-
tional study showed that, 20 min after administration of
neostigmine, 18% of patients had a TOF ratio < 0.9 [8].
Moreover, as shown in an animal study, when neostig-
mine is administered in the setting of full recovery from
a muscle relaxant, the drug can cause weakness of the
diaphragm and genioglossus muscle even if this effect is
not seen when residual curarization is still present [9].
Sugammadex is the first selective reversal agent for
steroidal NMBAs. It has been shown to give full and
rapid recovery of muscle strength, thus minimizing the
occurrence of PORC [8, 10].
The diaphragm, the major respiratory muscle in
humans, is a great septum between the thoracic and
abdominal cavities. The movement of the diaphragm
accounts for 60–70% of the total tidal volume of res-
piration. Failure of diaphragmatic function is believed
to play a central role in the pathophysiology of the
clinical syndrome known as “pump respiratory failure”
[11–13]. Although a TOF ratio > 0.9 in the adductor
pollicis rules out residual curarization, the diaphragm
is often not evaluated in the operating room. The dia-
phragm is the most highly resistant muscle to NMBAs,
as well as the first to recover [14], but the occurrence
of its dysfunction has been implicated in postoperative
respiratory failure, especially when mechanical ventila-
tion is prolonged [15, 16]. Therefore, studying dia-
phragmatic function in a perioperative context is
extremely important.
Since 1985, ultrasonography has been used to evaluate
diaphragm function by measuring thickness variations in
the apposition zone, which reflect the extent of contrac-
tion of the muscle [17]. Vivier et al. recently demonstrated
that the thickening fraction (TF), namely the difference
between the thickness at the end of inspiration (TEI) and
that at the end of expiration (TEE), normalized for TEE
(TEI – TEE/TEE), is directly related to respiratory work-
load, and they suggested that TF could be used as an index
to select those patients ready to be weaned from non-
invasive ventilation [18]. These data suggest that ultra-
sound TF could also be used in different scenarios, and
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our purpose is to use ultrasound TF to assess diaphragm
recovery after dNMB since it is more comfortable for con-
scious patients than acceleromyography.
We therefore hypothesize that the incidence of postop-
erative diaphragmatic dysfunction, assessed using ultra-
sonography and, from our unpublished observations,
defined by a fractional shortening of the diaphragm < 40%,
is lower in patients who receive sugammadex than in
those who receive neostigmine.
Methods/design
Study design and eligibility
This study is a prospective, double-blind, randomized
controlled trial involving 60 patients with American
Society of Anesthesiologists (ASA) physical status I–II
and aged between 18 and 80 years, who will undergo
dNMB (standard care in our clinic) with rocuronium
during ear, nose, or throat surgery in a university hos-
pital. The Institutional Review Board of the Tuscany
Region has approved the protocol with registration
number CE SPE 13.068. Exclusion criteria are a history
of hepatic or renal disease, chronic or acute alcoholism,
allergy or hypersensitivity to sugammadex or neostig-
mine, current medication with effects on the central
nervous system, a history of neurologic disease, dia-
phragmatic palsy, women who are pregnant or nursing,
and arrhythmias.
Randomization
Written informed consent will be obtained during the
preoperative evaluation by an anesthesiologist working
in the anesthesia unit of the hospital. Afterwards, each
patient will be randomly allocated to either the sugam-
madex (SUG) group or the neostigmine (NEO) group.
Randomization will be performed using a table created
on www.randomization.com. The allocation plan will be
carried out using a variable block randomization method
1:1 to distribute the patients equally to each group. For
allocation concealment, table assignment to one group
or the other will be managed by a pharmacist with lim-
ited involvement in the study; this person will also
perform the allocation and prepare the drugs.
Intervention plan
In order to standardize the anesthetic technique, no pre-
medication will be administered. All patients will undergo
neuromuscular monitoring with ulnar nerve stimulation
using the TOF-Watch (Organon, Oss, Netherlands). The
device will be calibrated preoperatively, and the parameters
will be set using standard TOF methodology after adminis-
tration of a hypnotic drug, prior to muscle relaxation.
General anesthesia will be induced by intravenous injection
of fentanyl (2 μg/kg body weight), propofol (2 mg/kg), and
rocuronium (0.6 mg/kg). Tracheal intubation will be
performed after the patient fails to register signals using
TOF. To maintain dNMB, rocuronium (0.15 mg/kg) will
be re-administered when the PTC elicits more than five
twitches. Sevoflurane will be supplied at an age-adjusted
end-tidal concentration of 1.0 minimum alveolar concen-
tration (MAC) in an air/oxygen mixture. Fentanyl will be
titrated with a bolus of 0.5 μg/kg every 30 min, to keep an
adequate level of analgesia.
Prior to induction of anesthesia, the baseline TF will
be evaluated by one operator skilled in ultrasonog-
raphy using an Esaote MyLab ultrasound instrument
(Esaote, Genoa, Italy). Patients will be placed on the
bed in a semi-recumbent (45°) position, assessed by a
goniometer. The operator will use a 10–12 MHz high-
frequency linear probe to identify the diaphragm in the
midaxillary line in the apposition zone between the
lung and liver on the right and between the lung and
spleen on the left, in the intercostal spaces between
the ninth, tenth, and eleventh ribs, 0.5–2 cm above the
costophrenic sinus. The TF will be calculated at tidal
breathing, recorded in time-motion mode. The muscle
will be located using the hyperechoic pleural and peri-
toneal layers. Three assessments will be performed in
consecutive breaths and averaged [18].
At the end of the operation and when TOF neuromuscu-
lar monitoring shows a minimum of two twitches, patients
will receive the reversal drug according to the group to
which they have been randomized. Patients in the NEO
group will receive 50 μg/kg neostigmine and 15 μg/kg atro-
pine, while those in the SUG group will receive 2 mg/kg
sugammadex [19]. The drugs will be prepared for intraven-
ous injection in identical volumes and in indistinguishable
syringes so that the anesthesiologist will be blinded to the
treatments the patients receive. Extubation will be per-
formed when all the following criteria are met: (1) the
patient is awake and can execute simple commands; (2)
the patient’s respiratory pattern is regular with a tidal vol-
ume of 6–7 mL/kg referred to ideal body weight; (3) the
TOF ratio is > 0.9. Immediately prior to extubation,
bilateral diaphragm ultrasonography will be performed to
assess muscle recovery in spontaneously breathing patients;
these measurements will be compared to the baseline
muscle assessment. Two additional diaphragm ultrasound
scans will be performed 10 and 30 min after discharge
from the operating theater under the same conditions as
described above, but no further TOF monitoring will be
carried out. Follow-up will be performed to document ad-
verse events and complications until discharge from the
hospital. The physician who performs the ultrasound scan
will be different from the one who administers the reversal
drug and will be blinded to the treatment that patients
receive (Figs. 1 and 2). The Standard Protocol Items: Rec-
ommendations for Interventional Trials (SPIRIT) checklist
is provided as Additional file 1.
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In the case of unexpected events, such as a change in
drug dose or a participant’s request to withdraw from
the study, the protocol will be stopped and this will be
recorded on the case report form (CRF). No further tests
will be performed except those necessary to finalize the
protocol. Should patients need medical care that inter-
feres with the correct conduct of the study, they will be
excluded from the study.
The primary endpoint of the study will be a 30% rela-
tive reduction in the incidence of residual curarization
in patients who receive sugammadex compared with
neostigmine 30 min after drug administration. The pri-
mary endpoint will be assessed at 30 min because the
effects of neostigmine start to fade after this time has
elapsed [20]. Residual curarization will be determined
by the percentage of 30 min TF compared to baseline
TF. It is not known exactly what percentage TF indi-
cates residual curarization, but from our unpublished
observations, values of 40% or less could indicate dia-
phragmatic dysfunction. However, we do not know
what percentage of patients have a TF < 40% when
neostigmine is administered.
Two secondary endpoints will be assessed. One sec-
ondary endpoint will be a 10% relative reduction in
respiratory complications related to residual curarization
obtained with sugammadex compared with neostigmine.
Respiratory complications taken into consideration will
be new cough and sputum production, abnormal breath
sounds not present at baseline, temperature higher than
38 °C, chest radiography documentation of atelectasis or
new infiltrates, and physician documentation of atelec-
tasis or pneumonia [21]. The other secondary endpoint
will be a 30% relative decrease in postoperative nausea
or vomiting in patients who receive sugammadex com-
pared with those who receive neostigmine.
Data monitoring will be performed by an anesthetist not
involved in the study. Data will be collected on paper
CRFs. All personal information will be registered in an
environment limited to medical personnel to maintain ab-
solute confidentiality. Data entry will be performed at one
STUDY PERIOD
Enrolment Allocation Post-allocation Close-out
TIMEPOINT
30 days
before 
surgery
DOS t1 t2 t3 t4 t5 t6 DOD
ENROLMENT:
Eligibility screen X
Informed consent X
[List other 
procedures] X
Allocation X
INTERVENTIONS:
[Sugammadex] X
[Neostigmine/
atropine] X
ASSESSMENTS:
Diaphragm 
Ultrasonography
X X X X
Neuromuscular 
monitoring
X X
PONV and RC
X
DOS = Day of Surgery
t1 = preanesthetic period
t2 = induction of anesthesia
t3 = end of anesthesia
t4 = extubation
t5 = 10 minutes after anesthesia
t6 = 30 minutes after anesthesia
DOD = Day of discharge
PONV = Post-operative Nausea and vomiting
RC = Respiratory Complications
Fig. 1 Study timeline
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central site that maintains the overall database and will
carry out the data analysis. All the compiled CRFs will be
archived in a locker to which only clinicians involved in
the study have access. In order to eliminate possible data
entry errors, individual data will be compared to a range
of plausible values. After data entry, automated checks,
which have been defined a priori, will be performed to
search for internal inconsistencies, range errors, or miss-
ing data. For each atypical, out-of-range, or missing
datum, a query will be automatically sent to the investiga-
tor. Once all the queries are solved, the database will be
locked and used for statistical analysis. All the individual
participant data collected during the trial, after de-
identification, will be available. The study protocol,
statistical analysis plan, and analytic code will be accessed
beginning 3 months and ending 5 years following article
publication by researchers who will provide a methodo-
logically sound proposal to achieve aims in the approved
proposal. Each request must be sent to the corresponding
author.
Statistical analyses and sample size calculation
The statistical analysis will be performed by an inde-
pendent statistician using SAS 9.3 (SAS Institute,
Inc., Cary, NC, USA). For the primary endpoint, the
effect of a drug on ΔTF will be estimated using gen-
eralized estimating equations (GEEs) and a multiple
linear regression model adjusting for time of the
measurement and baseline TF of the right side. This
hemidiaphragm has been chosen because it is more
easily identified for the presence of the liver. For the
secondary endpoint, the association between a drug
and its collateral effect will be evaluated using a lo-
gistic regression model. P values lower than 0.05 have
been considered statistically significant.
Finally, descriptive statistics of all variables describ-
ing the characteristics of the patients enrolled in the
study and those excluded from the study will be ana-
lyzed. Continuous variables will be expressed as mean
(± standard deviation, (SD)) and median (ranging
from 25th to 75th percentiles). Percentages will be
Fig. 2 Study flow diagram
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calculated for dichotomous data. For categorical vari-
ables, frequency counts and percentages will be
calculated.
Since this is the first clinical trial that proposes, as its
primary endpoint, a relative reduction of 30% in the in-
cidence of residual curarization, the necessary sample
size has been calculated using the statistical software
Epi Info (version 7). This analysis shows that at least
30 patients per group will be necessary, considering
that in 5% of subjects TF is not valuable [22, 23], and
expecting 23–25% of residual curarization with neo-
stigmine 30 min after the extubation vs. 2–4% after the
administration of sugammadex (with a 95% confidence
interval (CI) and a power of 80%, and assuming equal
variance between the two groups). For the secondary
outcome, the number needed to treat has been calcu-
lated with a CI of 95%.
Discussion
Diaphragm ultrasonography has been used for 25 years
to evaluate diaphragmatic dysfunction in many clinical
scenarios [18, 24–26]. Ultrasound assessment of the
diaphragm is not feasible if the operator is not
adequately trained, but when skilled operators are
available, this tool enables bedside evaluation of the
major respiratory muscle. We have observed (unpub-
lished observations) that the reproducibility and re-
peatability of diaphragm ultrasonography are moderate
when the test is performed by three different operators
with different levels of experience with sonography.
However, one potential limitation of the present proto-
col could be that previous studies have demonstrated
that repeatability ranges from 13 to 19% [22].
This study will be the first to assess if TF measure-
ments in the operating room enable physicians to
diagnose and eventually treat residual curarization
after dNMB. The rationale for comparing sugamma-
dex to neostigmine is that the latter has a pharmacoki-
netic profile that cannot avoid residual curarization,
especially when an intermediate or long-lasting muscle
relaxant is administered during general anesthesia,
while the former avoids residual curarization because
it binds stably with steroid NMBA molecules by
means of van der Waals and hydrophobic interactions
[27]. Therefore, the present study will be the first that
aims to detect diaphragmatic dysfunction using ultra-
sonography for the purpose of assessing PORC after
deep neuromuscular blockade with an aminosteroid
muscle relaxant drug.
Trial status
Currently, patient recruitment is completed and all data
have been collected. Data analysis will begin shortly.
Additional file
Additional file 1: SPIRIT 2013 checklist: recommended items to address
in a clinical trial protocol and related documents. (DOC 122 kb)
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